Calcitonin and Bone Biology

Thirty-two amino acids. That's all it takes to produce one of the more structurally elegant signalling molecules in vertebrate endocrinology. Calcitonin is a peptide hormone that has been studied for decades, and calcitonin and bone biology remain a source of interesting science, even if clinical attitudes toward it have shifted considerably since the 1980s.

I want to walk through the chemistry, the receptor biology, the pharmacokinetics, and the regulatory picture in Australia, because that last part is more nuanced than most overview articles let on. But first: the molecule itself.

What calcitonin is, structurally

Calcitonin belongs to a family of related peptides that includes calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and intermedin. They share enough structural similarity to be grouped as the calcitonin superfamily, and they all act through class B G protein-coupled receptors. Class B GPCRs, sometimes called secretin-like receptors, respond to relatively large peptide ligands, which puts calcitonin in good company alongside glucagon, PTH, and the GLP-1 receptor agonists.

In humans, calcitonin is produced primarily in the parafollicular C-cells of the thyroid gland. The precursor is preprocalcitonin: a 141-amino-acid protein that gets cleaved down to the mature 32-residue form. The mature peptide has a disulphide bridge between cysteine residues at positions 1 and 7; that ring structure at the N-terminus is conserved across species and is considered essential for receptor binding activity. There's also a C-terminal prolinamide, another conserved feature.

If the terminology is new, the building blocks of peptides are worth a quick read first, and the entry on cysteine explains why that residue is the one that forms disulphide bridges. A ring closed by a disulphide bond is a small-scale example of what cyclic peptides do more broadly: constrain the shape of a flexible chain so it presents the right surface to its receptor.

As a peptide of this size and polarity, calcitonin can't cross cell membranes by passive diffusion. It acts extracellularly, binding the calcitonin receptor (CTR) on the outer surface of target cells. The CTR is expressed most densely on osteoclasts, the large multinucleated cells responsible for bone resorption, and on certain renal tubule cells.

Calcitonin and bone biology: receptor signalling in osteoclasts

Osteoclasts are, in broad terms, the "teardown crew" of bone remodelling. They acidify the bone surface and secrete proteases to break down the mineralised collagen matrix, releasing calcium into the bloodstream. CTR activation on osteoclasts triggers a fairly rapid intracellular cascade, primarily through adenylyl cyclase and elevated cyclic AMP, that suppresses osteoclast activity. Morphologically, activated osteoclasts retract their ruffled border (the specialised membrane surface that interfaces with bone), and some studies have documented an acute reduction in resorptive activity within minutes of calcitonin exposure.

For readers who want the general mechanism, receptor binding, agonists and antagonists sets out what it means for a ligand to occupy a receptor and switch on a signalling pathway. The key idea here is that the cyclic AMP rise is a second messenger: one receptor event is amplified inside the cell into a broad change in behaviour.

Calcitonin's physiological role in humans is, honestly, still contested. In species like fish and birds, where rapid calcium shifts are more physiologically pressing, calcitonin appears to have a more dominant regulatory function. In adult humans, its contribution to calcium homeostasis seems less decisive than that of parathyroid hormone (PTH) and vitamin D. Patients who have had their thyroid removed, and who therefore have little circulating calcitonin, don't generally develop obvious hypercalcaemia if PTH and vitamin D axes are intact. I'll admit that nuance is often glossed over in older endocrinology texts.

That said, calcitonin's pharmacological effects at supraphysiological doses (i.e., therapeutic concentrations) are real and have been characterised in numerous studies. The osteoclast suppression is measurable. The renal effects, increased excretion of calcium, phosphate, and sodium via inhibition of tubular reabsorption, are also documented. Whether those effects translate to durable clinical benefit is a separate question, and one where the evidence is much messier. A measurable effect on a cell type in the lab is a mechanism; it isn't an outcome, and the two should never be confused.

Pharmacokinetics: why delivery route matters a lot

This is the part I find genuinely interesting as someone who spends a lot of time thinking about pharmacokinetics. Calcitonin is a peptide, so oral bioavailability via the conventional gastrointestinal route is effectively zero; proteases in the gut and the low-pH environment of the stomach would degrade it before any meaningful absorption could occur. This is the same fundamental challenge facing insulin, GLP-1 analogues, and many other therapeutic peptides. The reasoning is laid out in why most peptides are injectable, and the wider framework is in peptide pharmacokinetics.

Injectable salmon calcitonin (sCT) has been the dominant pharmaceutical form because salmon calcitonin has roughly 40–50 times higher potency at the human CTR compared to human calcitonin, and its longer plasma half-life makes the pharmacodynamic picture a bit more workable. Subcutaneous injection and intramuscular injection both give reasonable absorption, though peak plasma concentrations and half-lives differ. Nasal spray formulations were developed partly to address tolerability issues with injection, and the intranasal route gives lower and more variable bioavailability, typically cited in the range of 3–5% relative to parenteral administration, but the nasal mucosa bypasses first-pass metabolism, which matters.

Metabolism is primarily renal and enzymatic, with a reported plasma half-life of roughly 60–90 minutes for salmon calcitonin given subcutaneously, though figures vary across published studies. That relatively short half-life shaped the dosing frequency in historical clinical programmes. When you see a half-life quoted, it's worth checking the species, the route and the assay used, because each of those can move the number.

The regulatory picture in Australia

Here's where things get specific. Calcitonin-containing medicines in Australia are regulated by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act 1989. Any medicine containing calcitonin that is supplied for therapeutic use in Australia must be listed or registered on the Australian Register of Therapeutic Goods (ARTG). Products that aren't on the ARTG cannot be lawfully supplied commercially.

Prescription medicines containing calcitonin fall under Schedule 4 of the Poisons Standard, meaning they require a valid prescription from a registered prescriber. Patients seeking access to medicines not available on the ARTG may apply through the Special Access Scheme, and prescribers with relevant expertise can apply to become an Authorised Prescriber for unapproved medicines where a clinical justification exists.

It's also worth being direct about the broader peptide supply landscape. Many peptides, calcitonin included, circulate in online markets positioned at research or performance contexts. The TGA has been explicit and active in enforcing that supplying unapproved peptide products without the appropriate ARTG registration, SAS approval, or prescription pathway is illegal in Australia. This applies regardless of how a product is labelled or marketed. Anyone encountering peptides being sold without a clear regulatory pathway in Australia should understand those products fall outside the law. The peptide science and safety FAQ covers the general questions readers tend to ask.

How salmon calcitonin became the standard pharmaceutical form

The short version is: evolution gave salmon calcitonin a molecular structure that happens to be an unusually good fit for the human CTR. The human and salmon sequences share about 50% identity, which is surprisingly low, yet sCT's potency advantage at the human receptor is well-established in receptor binding and in vivo studies. This is actually a recurring theme in peptide pharmacology: the "natural" human form isn't always the most pharmacologically active option at the target receptor. Small sequence differences can change how tightly a peptide sits in the binding pocket and how long it stays there, which is the logic behind peptide folding and tertiary structure.

Synthetic sCT has been produced since the early 1970s via solid-phase peptide synthesis. The amino acid sequence was confirmed and chemical synthesis followed relatively quickly after isolation of the natural peptide. The peptide bonds in the synthetic form are chemically identical to the natural peptide, which matters for receptor recognition, but the manufacturing and purity controls are, naturally, far more stringent in pharmaceutical-grade production than in anything circulating outside approved channels. Purity, identity and sterility are things a consumer can't verify by looking at a vial, which is exactly why approved supply chains exist.

Calcitonin and medullary thyroid carcinoma: the diagnostic angle

One genuinely underappreciated aspect of calcitonin biology is its diagnostic use. C-cells are the origin of medullary thyroid carcinoma (MTC), and calcitonin is a well-established tumour marker for that malignancy. Serum calcitonin measurement, sometimes with pentagastrin or calcium stimulation, is used in the workup and monitoring of MTC. This has nothing to do with exogenous calcitonin administration; it's purely about measuring the endogenous peptide as a biological signal of C-cell activity.

The reason I bring this up: when reading research literature on calcitonin, the diagnostic and therapeutic literatures overlap and can be confusing. Studies on calcitonin levels in patients, or on calcitonin secretion dynamics, often have nothing to do with exogenous therapeutic use. Worth keeping straight.

Context shapes interpretation, and that's as true for peptide research as it is for any evidence. A number without provenance is just a number. Before drawing anything from a calcitonin paper, check what was measured, in whom, and why.

What the research landscape looks like now

The clinical use of calcitonin has narrowed considerably from its peak. The European Medicines Agency reviewed the benefit-risk balance of nasal calcitonin products in 2012 and concluded the risk of malignancy (a small but consistent signal in long-term trials) outweighed the benefits for chronic use in the indications then approved in Europe. Regulatory actions followed in multiple jurisdictions.

Current research interest has shifted somewhat toward CGRP and amylin, calcitonin superfamily members, where the therapeutic pipeline is more active. CGRP-targeted therapies have attracted significant attention in migraine research, and the biology of the calcitonin receptor/receptor activity-modifying protein (RAMP) complexes is a genuinely active area of structural pharmacology. For calcitonin specifically, the MTC diagnostic application remains solid science.

My honest view: calcitonin's story is a good reminder that a pharmacologically active molecule and a safe, effective medicine are not the same thing. The receptor biology is elegant. The clinical history is a lesson in the importance of long-term evidence and regulatory review. Both parts of that story are worth understanding.

Sources

• Regulation of peptide medicines; Therapeutic Goods Administration (TGA)
• Calcitonin: Biochemistry and physiology, StatPearls, NCBI
• Calcitonin Article-31 referral assessment report, European Medicines Agency
• Calcitonin receptor pharmacology; British Journal of Pharmacology (PMC)

Priya Nandakumar, Pharmacology writer, peptides & PK